School of Medicine
Showing 1-10 of 14 Results
Professor of Radiology (Pediatric Radiology) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests Advanced imaging, including magnetic resonance imaging, of injury to the developing central nervous system; including fetal, neonatal, infant and young child; and, including nonaccidental injury (e.g. child abuse).
Professor of Radiology (Pediatric Radiology) at the Stanford University Medical Center
Current Research and Scholarly Interests Magnetic Resonance Imaging and Sonographic diagnosis of fetal anomalies.
Focus interest in the diagnosis and conservative (non-surgical and minimal radiation) management of congenital broncho pulmonary malformations.
Imaging of appendicitis in children.
Sonography of the pediatric testis.
Christopher Beaulieu M.D., Ph.D.
Professor of Radiology (Musculoskeletal Imaging) and, by courtesy, of Orthopaedic Surgery at the Stanford University Medical Center
Current Research and Scholarly Interests Informatics and image processing techniques that provide infrastructure for diagnosis in musculoskeletal imaging. Decision support for improving accuracy of bone tumor diagnosis. Improved methods for MRI in the musculoskeletal system.
Professor of Radiology (Cardiovascular Imaging) at the Stanford University Medical Center
Current Research and Scholarly Interests Myocardial bridges (MB) with associated upfront atherosclerotic lesions are common findings on coronary computed tomography angiography (CTA). Abnormal septal wall motion in exercise echocardiography (EE) may to be associated with MB. Intravascular ultrasound (IVUS) is considered the gold standard for the detection of MB. We investigate whether CTA is comparable to IVUS for the assessment of MB and upstream plaques in symptomatic patients with suspicion for MB raised by EE.
Instructor, Radiology - Rad/Molecular Imaging Program at Stanford
Current Research and Scholarly Interests My current research areas of interest include developing new strategies for: 1) novel radioligand and radiotracer development for various targets involved in brain cancer, 2) preclinical animal models of glioblastoma, and 3) clinical translation of useful radiopharmaceuticals for early-detection of disease and monitoring therapy.
Director, ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Radiology and of Chemical and Systems Biology
Bio Professor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, and the ACS Award in Pure Chemistry, among many others. Her efforts in undergraduate education have earned the UC Berkeley Distinguished Teaching Award and the Donald Sterling Noyce Prize for Excellence in Undergraduate Teaching.
Today, the Bertozzi Group at Stanford studies the glycobiology underlying diseases such as cancer, inflammatory disorders such as arthritis, and infectious diseases such as tuberculosis. The work has advanced understanding of cell surface oligosaccharides involved in cell recognition and inter-cellular communication.
Dr. Bertozzi's lab also develops new methods to perform controlled chemical reactions within living systems. The group has developed new tools for studying glycans in living systems, and more recently nanotechnologies for probing biological systems. Such "bioorthogonal" chemistries enable manipulation of biomolecules in their living environment.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi founded Redwood Bioscience of Emeryville, California, and has served on the research advisory board of GlaxoSmithKline.